Mendell Helium PLC - Fundraise, Warrants and Issue of Equity
Announcement provided by
Mendell Helium plc · MDH07/04/2025 07:00

7 April 2025
Mendell Helium plc
("Mendell Helium" or the "Company")
Fundraise, Warrants and Issue of Equity
Director / PDMR Shareholding and Related Party Transaction
Mendell Helium is pleased to announce that the Company has raised approximately £796,000 by way of a placing ("Placing") and subscription ("Subscription") (together "Fundraise") through the issue of 39,807,950 new ordinary shares of
As announced on 27 June 2024, the Company has an option (the "Option") to acquire M3 Helium Corporation ("M3 Helium"), a producer of helium which is based in
In conjunction with the re-admission of the enlarged group, the Company is exploring opportunities to also admit its shares to trading on alternative
Placing
As part of the Fundraise, the Company has raised gross proceeds of
Subscription
In addition to the Placing, the Company has raised gross proceeds of
Director Participation & Director / PDMR Shareholding
As part of the Subscription, Eric Boyle, Non-Executive Chairman, has subscribed for
Director |
Amount subscribed for in the Subscription |
Number of Subscription Shares |
Number of Warrants |
Resultant shareholding following Admission |
Eric Boyle |
|
500,000 |
500,000 |
3,087,474 |
Related Party Transaction
The Director Participation (the "Transaction") is a related party transaction for the purposes of Rule 4.6 of the AQSE Growth Market Access Rulebook. Nick Tulloch, the director of Mendell Helium independent of the Transaction confirms that, having exercised reasonable care, skill and diligence, the Transaction is fair and reasonable insofar as the shareholders of Mendell Helium are concerned.
Issue of Warrants
For every New Ordinary Share issued pursuant to the Fundraise, investors will receive one warrant allowing the holder to subscribe for an additional Ordinary Share in the Company at an exercise price of
In connection with the Fundraise, the Company will issue, on completion of the Fundraise, 675,000 warrants to brokers who arranged the Placing and Subscription ("Broker Warrants"). The Broker Warrants shall be exercisable at
Following the Fundraise, the Company will have authority to issue a further 192,050 new ordinary shares in the Company. Accordingly, and to enable the Warrants and the Broker Warrants to be exercisable in due course, it is Mendell Helium's intention to shortly convene a general meeting to seek shareholder approval to issue new ordinary shares in the Company.
Use of Proceeds
The gross proceeds of approximately
· to bring M3 Helium's Rost 1-26 well into production
· to progress new opportunities around the
· to settle the preliminary payment of
· for general working capital requirements.
The loan facility that has been provided by Mendell Helium to M3 Helium will be extended to reflect the deployment of funds outlined above, and a further announcement will be made in due course.
The Company noted investor sentiment in the Fundraise towards the Company considering seeking admission of its shares to trade on an alternative
Admission
Application will be made for the New Ordinary Shares to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market ("Admission"). Admission is expected to occur at 8:00 am on or around 14 April 2025. The New Ordinary Shares will rank pari passu with the existing ordinary shares.
Total Voting Rights
Following Admission, the Company's enlarged share capital will comprise 83,693,444 ordinary shares of
Nick Tulloch, Chief Executive Officer of Mendell Helium and Chairman of M3 Helium, said: "I am delighted to announce that, notwithstanding the challenging market conditions, the quality of M3 Helium's assets has resulted in strong support for our fundraising from investors.
"The funds raised will primarily be allocated to complete the development of M3 Helium's Rost well. We are now fully funded to bring one of the most exciting helium opportunities in
This announcement contains inside information for the purposes of the
ENDS
Enquiries:
Mendell Helium plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
nick@mendellhelium.com https://mendellhelium.com/ |
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Ludovico Lazzaretti / Liam Murray
|
Tel: +44 (0) 20 7213 0880 |
SI Capital Limited (Broker)
Nick Emerson |
Tel: +44 (0) 1483 413500 |
Stanford Capital Partners Ltd (Broker)
Patrick Claridge/Bob Pountney
|
Tel: +44 (0) 203 3650 3650/51
|
Fortified Securities (Placing agent)
Guy Wheatley
|
Tel: +44 (0) 203 4117 773
|
Brand Communications (Public & Investor Relations)
Alan Green
|
Tel: +44 (0) 7976 431608
|
Overview of M3 Helium
Mendell Helium, formerly Voyager Life plc, announced on 27 June 2024 that it has entered into an option agreement to acquire the entire issued share capital of M3 Helium through the issue of 57,611,552 new ordinary shares in Mendell Helium to M3 Helium's shareholders. The exercise of the option will constitute a reverse takeover pursuant to AQSE Rule 3.6 of the Access Rule Book and is subject to, inter alia, publication of an admission document.
M3 Helium has interests in nine wells in South-Western Kansas of which five (Peyton, Smith, Nilson, Bearman and Demmit) are in production. Eight of the company's wells are within the
The ninth well, Rost, is in
1 |
Details of the persons discharging managerial responsibilities / person closely associated
|
||||||||||
a) |
Name
|
Eric Boyle |
|||||||||
2 |
Reason for the notification
|
||||||||||
a) |
Position/Status
|
Non-executive Chairman |
|||||||||
b) |
Initial notification/ Amendment
|
Initial |
|||||||||
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||||||||
a) |
Name
|
Mendell Helium plc |
|||||||||
b) |
LEI
|
213800XIUQ3AHRZ6UF89 |
|||||||||
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||||||||
a) |
Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of
GB00BLD3FF28
|
|||||||||
b) |
Nature of the transaction |
Participation in the Subscription Warrants attached to the Fundraise with an exercise price of |
|||||||||
c) |
Price(s) and volume(s)
|
|
|||||||||
d) |
Aggregated information
- Aggregated volume
- Price
|
|
|||||||||
e) |
Date of transaction
|
7 April 2025 |
|||||||||
f) |
Place of transaction
|
AQSE |
FORWARD LOOKING STATEMENTS
This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could" or "similar" expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.